Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03652961 · ClinicalTrials.gov registry record · Phase 4
Rheumatoid Arthritis Memory B Cells and Abatacept
A Phase 4 study, sponsored by NYU Langone Health.
- Completed
- Registry status
- Phase 4
- Development phase
- 25
- Enrollment target
NCT03652961: Completed Phase 4 study, sponsored by NYU Langone Health.
NCT03652961 is a Phase 4 study that has completed, run by NYU Langone Health. The registered enrollment target is 25 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03652961, a Phase 4 study, has completed, sponsored by NYU Langone Health.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 25 participants
- Enrollment target
Study Summary
Single-Open Label Study to Assess Changes in the Immune Profile in Response to Treatment with Intravenous Abatacept Adults with Rheumatoid Arthritis who are Naive to Biologic Disease-Modifying Antirheumatic Drugs
Primary Outcome
Clinical Disease Activity Index (CDAI) is a composite index used to assess rheumatoid arthritis (RA) disease activity. The CDAI score is the sum of the Swollen 28-Joint Count (SJC28) + Tender 28-Joint Count (TJC) + Patient Global disease Activity (PGA, patient's assessment of overall RA disease activity on a scale 1-10 where 10 is maximal activity) + Evaluator's Global disease Activity (EGA, evaluator's assessment of overall RA disease activity on a scale 1-10 where 10 is maximal activity). The
Interventions
- DRUG Abatacept
- DRUG DMARDs
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2019-06-02 |
| Est. Completion | 2021-09-27 |
| Phase | Phase 4 |
What the finished NCT03652961 record still lists
NCT03652961 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (95% lower).
The record links to 0 conditions, and to 2 interventions - of which Abatacept is the first listed.
NCT03652961 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03652961 about?
NCT03652961 is a clinical study titled "Rheumatoid Arthritis Memory B Cells and Abatacept". Single-Open Label Study to Assess Changes in the Immune Profile in Response to Treatment with Intravenous Abatacept Adults with Rheumatoid Arthritis who are Naive to Biologic Disease-Modifying Antirheumatic Drugs
What is the current status of trial NCT03652961?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 25 participants. The study started on 2019-06-02. Estimated completion is 2021-09-27.
What interventions are being tested in trial NCT03652961?
The interventions under investigation include: Abatacept (DRUG), DMARDs (DRUG).
Who is sponsoring clinical trial NCT03652961?
This trial is sponsored by NYU Langone Health, which has 1,164 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT03652961's enrollment target sits among peer trials
25 1669th of 2000 higher than 302 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI